Search
Now showing items 1-9 of 9
Article
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19
| Date Issued:
2021 | Copyright:
open access
Article
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
| Date Issued:
2017 | Copyright:
open access
Article
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production
| Date Issued:
2020 | Copyright:
open access
Article
Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts
| Date Issued:
2022 | Copyright:
open access
Article
Aureonitol, a Fungi-Derived Tetrahydrofuran, Inhibits Influenza Replication by Targeting Its Surface Glycoprotein Hemagglutinin
| Date Issued:
2015 | Copyright:
open access
Article
Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo
| Date Issued:
2019 | Copyright:
open access
Article
2,8-bis (trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine
| Date Issued:
2017 | Copyright:
restricted access
Article
N-(2-(arylmethylimino)ethyl)-7-chloroquinolin-4-amine derivatives, synthesized by thermal and ultrasonic means, are endowed with anti-Zika virus activity
| Date Issued:
2017 | Copyright:
open access
Article
Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators
| Date Issued:
2020 | Copyright:
open access